Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Tislelizumab in Platinum-refractory Bladder Cancer
NCT06364956Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib in bladder urothelial carcinoma (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Safety dose of the combination of Tislelizumab and Palbociclib at 12 months and Pathological Complete Response at 24 months. Started May 2024; status: recruiting.
02
Drugs
palbociclib
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT06364956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364956.